ILUMIEN IV: OPTIMAL PCI

  • Research type

    Research Study

  • Full title

    OPtical Coherence Tomography (OCT) Guided Coronary Stent IMplantation Compared to Angiography: a Multicenter Randomized TriaL in PCI

  • IRAS ID

    242628

  • Contact name

    Jonathan Hill

  • Contact email

    jmhill@nhs.net

  • Sponsor organisation

    Abbott Vascular (formerly St Jude Medical)

  • Clinicaltrials.gov Identifier

    NCT03507777

  • Clinicaltrials.gov Identifier

    n/a, n/a

  • Duration of Study in the UK

    5 years, 0 months, 7 days

  • Research summary

    Coronary Artery Disease is the narrowing or blockage of the coronary arteries, usually caused by the build-up of cholesterol and fatty deposits in the walls of the arteries. This blockage can slow down the blood flow carrying oxygen and vital nutrients to the heart and in turn cause chest pain and potentially a heart attack.

    A Coronary Angiogram shows an image of the coronary arteries and is used to check if there are any narrowing/ blockages. A possible treatment for this is called percutaneous coronary intervention (PCI) where a stent is implanted in the blocked /narrowed arteries to help open them up.

    This study is a prospective, single-blind, international, multi-centre randomised trial. Patients undergoing coronary angiography with the possibility of Percutaneous coronary intervention (PCI) will be recruited to the study.

    The purpose of this study is to compare the use of two imaging methods to assess how they influence the decision making process for coronary stent implantation

    Patients who are eligible to participate will be randomised to one of the 2 imaging groups below while undergoing a routine PCI:

    (1) Optical Coherence Tomography (OCT) - This method uses light waves to generate a high resolution of images of the inside of the vessels of the heart.

    (2) Angiography - Type of x-ray using contrast dye to identify narrowed/blocked blood vessels.

    After hospital discharge, all patients will have a clinical follow up at 30 days 1 year and 2 years.

    Once patients have provided consent to be part of the study, they will adhere to the requirements of the study protocol. All procedures required by the protocol are routine standard of care and participation in this trial carries no additional risk to the patient.

  • REC name

    London - Dulwich Research Ethics Committee

  • REC reference

    18/LO/1193

  • Date of REC Opinion

    21 Sep 2018

  • REC opinion

    Further Information Favourable Opinion